Chromatin Regulator CHD1 Remodels the Immunosuppressive Tumor Microenvironment in PTEN-Deficient Prostate Cancer
©2020 American Association for Cancer Research..
Genetic inactivation of PTEN is common in prostate cancer and correlates with poorer prognosis. We previously identified CHD1 as an essential gene in PTEN-deficient cancer cells. Here, we sought definitive in vivo genetic evidence for, and mechanistic understanding of, the essential role of CHD1 in PTEN-deficient prostate cancer. In Pten and Pten/Smad4 genetically engineered mouse models, prostate-specific deletion of Chd1 resulted in markedly delayed tumor progression and prolonged survival. Chd1 deletion was associated with profound tumor microenvironment (TME) remodeling characterized by reduced myeloid-derived suppressor cells (MDSC) and increased CD8+ T cells. Further analysis identified IL6 as a key transcriptional target of CHD1, which plays a major role in recruitment of immunosuppressive MDSCs. Given the prominent role of MDSCs in suppressing responsiveness to immune checkpoint inhibitors (ICI), our genetic and tumor biological findings support combined testing of anti-IL6 and ICI therapies, specifically in PTEN-deficient prostate cancer. SIGNIFICANCE: We demonstrate a critical role of CHD1 in MDSC recruitment and discover CHD1/IL6 as a major regulator of the immunosuppressive TME of PTEN-deficient prostate cancer. Pharmacologic inhibition of IL6 in combination with immune checkpoint blockade elicits robust antitumor responses in prostate cancer.This article is highlighted in the In This Issue feature, p. 1241.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Cancer discovery - 10(2020), 9 vom: 02. Sept., Seite 1374-1387 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhao, Di [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 29.11.2021 Date Revised 24.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1158/2159-8290.CD-19-1352 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM309683130 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM309683130 | ||
| 003 | DE-627 | ||
| 005 | 20231227140644.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1158/2159-8290.CD-19-1352 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1237.xml |
| 035 | |a (DE-627)NLM309683130 | ||
| 035 | |a (NLM)32385075 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhao, Di |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Chromatin Regulator CHD1 Remodels the Immunosuppressive Tumor Microenvironment in PTEN-Deficient Prostate Cancer |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.11.2021 | ||
| 500 | |a Date Revised 24.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a ©2020 American Association for Cancer Research. | ||
| 520 | |a Genetic inactivation of PTEN is common in prostate cancer and correlates with poorer prognosis. We previously identified CHD1 as an essential gene in PTEN-deficient cancer cells. Here, we sought definitive in vivo genetic evidence for, and mechanistic understanding of, the essential role of CHD1 in PTEN-deficient prostate cancer. In Pten and Pten/Smad4 genetically engineered mouse models, prostate-specific deletion of Chd1 resulted in markedly delayed tumor progression and prolonged survival. Chd1 deletion was associated with profound tumor microenvironment (TME) remodeling characterized by reduced myeloid-derived suppressor cells (MDSC) and increased CD8+ T cells. Further analysis identified IL6 as a key transcriptional target of CHD1, which plays a major role in recruitment of immunosuppressive MDSCs. Given the prominent role of MDSCs in suppressing responsiveness to immune checkpoint inhibitors (ICI), our genetic and tumor biological findings support combined testing of anti-IL6 and ICI therapies, specifically in PTEN-deficient prostate cancer. SIGNIFICANCE: We demonstrate a critical role of CHD1 in MDSC recruitment and discover CHD1/IL6 as a major regulator of the immunosuppressive TME of PTEN-deficient prostate cancer. Pharmacologic inhibition of IL6 in combination with immune checkpoint blockade elicits robust antitumor responses in prostate cancer.This article is highlighted in the In This Issue feature, p. 1241 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Chd1 protein, mouse |2 NLM | |
| 650 | 7 | |a DNA-Binding Proteins |2 NLM | |
| 650 | 7 | |a Smad4 Protein |2 NLM | |
| 650 | 7 | |a Smad4 protein, mouse |2 NLM | |
| 650 | 7 | |a PTEN Phosphohydrolase |2 NLM | |
| 650 | 7 | |a EC 3.1.3.67 |2 NLM | |
| 650 | 7 | |a Pten protein, mouse |2 NLM | |
| 650 | 7 | |a EC 3.1.3.67 |2 NLM | |
| 700 | 1 | |a Cai, Li |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Liang, Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Jiexi |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Peiwen |e verfasserin |4 aut | |
| 700 | 1 | |a Ittmann, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Shang, Xiaoying |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Shan |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Haoyan |e verfasserin |4 aut | |
| 700 | 1 | |a Meng, Chenling |e verfasserin |4 aut | |
| 700 | 1 | |a Flores, Ivonne |e verfasserin |4 aut | |
| 700 | 1 | |a Song, Jian H |e verfasserin |4 aut | |
| 700 | 1 | |a Horner, James W |e verfasserin |4 aut | |
| 700 | 1 | |a Lan, Zhengdao |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Chang-Jiun |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Chang, Qing |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Ko-Chien |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Guocan |e verfasserin |4 aut | |
| 700 | 1 | |a Deng, Pingna |e verfasserin |4 aut | |
| 700 | 1 | |a Spring, Denise J |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Y Alan |e verfasserin |4 aut | |
| 700 | 1 | |a DePinho, Ronald A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer discovery |d 2011 |g 10(2020), 9 vom: 02. Sept., Seite 1374-1387 |w (DE-627)NLM215937023 |x 2159-8290 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2020 |g number:9 |g day:02 |g month:09 |g pages:1374-1387 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1158/2159-8290.CD-19-1352 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2020 |e 9 |b 02 |c 09 |h 1374-1387 | ||